The role of dysregulated glucagon secretion in type 2 diabetes.
about
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMPPancreatic β Cell Mass DeathComprehensive Review on Kisspeptin and Its Role in Reproductive DisordersAddressing unmet medical needs in type 2 diabetes: a narrative review of drugs under developmentSomething old, something new and something very old: drugs for treating type 2 diabetesPhysiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseaseModulation of glucose transporter protein by dietary flavonoids in type 2 diabetes mellitusThere is Kisspeptin - And Then There is KisspeptinCytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infectionThe Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 DiabetesGlucagon regulates hepatic kisspeptin to impair insulin secretionEating two larger meals a day (breakfast and lunch) is more effective than six smaller meals in a reduced-energy regimen for patients with type 2 diabetes: a randomised crossover studyCyclic AMP sensor EPAC proteins and energy homeostasis.Human monoclonal antibodies against glucagon receptor improve glucose homeostasis by suppression of hepatic glucose output in diet-induced obese mice.Dipeptidyl peptidase-4 inhibitor (vildagliptin) improves glycemic control after meal tolerance test by suppressing glucagon releaseImpact of Chronic Periodontitis on Levels of Glucoregulatory Biomarkers in Gingival Crevicular Fluid of Adults with and without Type 2 Diabetes.Pancreatic α Cells are Resistant to Metabolic Stress-induced Apoptosis in Type 2 Diabetes.Esculentin-2CHa-Related Peptides Modulate Islet Cell Function and Improve Glucose Tolerance in Mice with Diet-Induced Obesity and Insulin Resistance.Dynamic monitoring of glucagon secretion from living cells on a microfluidic chip.Differentially Expressed MicroRNA-483 Confers Distinct Functions in Pancreatic β- and α-Cells.Receptor oligomerization in family B1 of G-protein-coupled receptors: focus on BRET investigations and the link between GPCR oligomerization and binding cooperativity.Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin SensitivityHepatic proteomic analysis revealed altered metabolic pathways in insulin resistant Akt1(+/-)/Akt2(-/-) miceAngptl4 links α-cell proliferation following glucagon receptor inhibition with adipose tissue triglyceride metabolism.Lysosomal integral membrane protein Sidt2 plays a vital role in insulin secretion.HIF2α Is an Essential Molecular Brake for Postprandial Hepatic Glucagon Response Independent of Insulin Signaling.Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist.Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetesInactivation of specific β cell transcription factors in type 2 diabetes.Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.A novel experimental strategy to assess the metabolic effects of selective activation of a G(q)-coupled receptor in hepatocytes in vivo.Novel insights into M3 muscarinic acetylcholine receptor physiology and structure.Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels.Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspectiveBasal hypersecretion of glucagon and insulin from palmitate-exposed human islets depends on FFAR1 but not decreased somatostatin secretionHepatic β-arrestin 2 is essential for maintaining euglycemia.Inhibition of the malate-aspartate shuttle in mouse pancreatic islets abolishes glucagon secretion without affecting insulin secretion.Role of histamine H3 receptor in glucagon-secreting αTC1.6 cellsAMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B.
P2860
Q22251081-96BB5CBF-1D77-4DA7-ADF2-ABC6C7A7E2F0Q26752571-EF79EECB-72AF-458E-A993-D67D697886E3Q26801682-94D3086A-8271-48C0-8FDB-634C8FF585F8Q26830274-598B5270-1542-44F6-A491-8AF066DC466BQ26865663-633352A9-89FA-4248-8DFF-21E4AC709F9DQ27027920-5D61C444-13E6-41D5-A214-D284BBCE9A73Q28081094-9CDA6B2E-6BDB-4351-87DD-595E03C4067FQ28088549-FB3BE970-6A68-499D-9117-82200794FBA3Q28480545-94717AB7-C7D9-4CD0-B01A-564C2BDD5AADQ28546913-9048A420-5210-4521-BE2C-B3E97F2F5A25Q30406016-D2BFECF9-B7C3-491C-8D42-E00DE62343BAQ33839305-E8400FDC-88FE-4E2B-8A19-4DB8FC67314EQ34385094-0150CE8F-269D-45F7-A552-30D031CF74C9Q34506664-9F623210-8334-4A06-80A1-3459B2648BC7Q34727768-7FDFB637-224E-45A5-B60A-C6A4D3047914Q35628627-AAF834D9-DF6A-420F-9ECD-9390E4A21C5DQ35799671-75F6C422-81FF-4651-B64D-D04DFF668213Q35825907-94E873BA-FF1A-47AE-B19E-3D606E02DB8CQ35883230-123B869E-40C9-4AF1-B1E5-C36BDC414B08Q35925909-450A4700-BDF6-441B-A494-12E85A149EF4Q35971449-9E165FB3-9FD9-4194-907A-11B63447E5C6Q36104668-7DF4FAD9-9C97-4E07-9F00-A420E14E505AQ36271468-218E3AC7-6FDC-4BFD-947F-F774E68AD603Q36394289-A3F5BC07-83A6-4511-8750-2698A7BF472DQ36511675-1370D0C7-F41B-4632-9C7F-68E19A156424Q36669733-1B7D05AA-254F-4903-B356-6B95EA777F32Q36913461-9CE035F2-8300-4686-A7F9-2B4B99ABAF02Q36993549-6F81353F-71BE-4F34-A026-8C753B08B84DQ37052883-53F43672-0C1F-41B0-A3E3-C8417D4D25D9Q37119965-A1320A58-AEEB-4644-B577-D2036A71B6BAQ37181904-7CFDCAD0-1CEC-41AF-8516-279118E925AFQ37666222-DB50AD4C-5B7B-42BD-9AD1-0CD51F4E1BCAQ37707996-10A59F94-7407-4642-9CAF-5E04EA7BCD84Q38014516-BC0C8CC7-E086-4BDB-B664-B3A47E9D3A5CQ38285665-CFF9F849-6FBC-4179-9F57-DB992977EFF4Q38697995-D917DFB0-9965-412B-8A24-A03B72E9C697Q38709127-C0F35580-8519-4455-A75E-F0CAE39792E6Q38904596-F5192936-1241-4663-8784-7B2743E0637AQ38909178-4C6CD9D4-5174-44B3-8D49-E8C12501477DQ38917281-554525D8-D1DA-44FB-AF96-A959BE90F0A7
P2860
The role of dysregulated glucagon secretion in type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The role of dysregulated glucagon secretion in type 2 diabetes.
@en
The role of dysregulated glucagon secretion in type 2 diabetes.
@nl
type
label
The role of dysregulated glucagon secretion in type 2 diabetes.
@en
The role of dysregulated glucagon secretion in type 2 diabetes.
@nl
prefLabel
The role of dysregulated glucagon secretion in type 2 diabetes.
@en
The role of dysregulated glucagon secretion in type 2 diabetes.
@nl
P2860
P1476
The role of dysregulated glucagon secretion in type 2 diabetes.
@en
P2093
D D'Alessio
P2860
P304
P356
10.1111/J.1463-1326.2011.01449.X
P478
13 Suppl 1
P577
2011-10-01T00:00:00Z